Singapore's Groundbreaking Discovery: Lung Cancer's Elusive 'Bodyguard System'

Singaporean researchers at the Agency for Science, Technology and Research (A*STAR)'s Institute of Molecular and Cell Biology (IMCB) have unveiled a novel protective mechanism in lung cancer cells, dubbed the 'bodyguard system.' This discovery sheds light on why certain lung cancers resist targeted therapies, offering new avenues for treatment. Published on January 21, 2026, in the prestigious journal Science Advances, the study highlights how cancer cells recruit molecular guardians to shield mutant epidermal growth factor receptor (EGFR) proteins from degradation, enabling tumor survival despite drugs like osimertinib.

Led by Senior Principal Investigator Dr. Gandhi Boopathy and co-corresponding author Dr. Hong Wee, the team conducted a genome-wide CRISPR knockout screen on osimertinib-resistant non-small cell lung cancer (NSCLC) cells. NSCLC, the most common lung cancer type accounting for about 85% of cases globally, frequently harbors activating EGFR mutations—particularly prevalent in Southeast Asia at 40-60% of adenocarcinoma cases.

"We found that cancer cells deploy molecular 'bodyguards' to shield the mutant protein from being broken down," explained Dr. Boopathy. This breakthrough not only explains drug resistance but also points to actionable targets in the tumor microenvironment.

Unraveling the Mechanism: Step-by-Step Breakdown of the Bodyguard System

The bodyguard system revolves around the purinergic receptor P2Y2 (full name: P2Y purinoceptor 2), a G-protein coupled receptor typically involved in sensing extracellular nucleotides like adenosine triphosphate (ATP).

• Step 1: Stressed or dying lung cancer cells release high levels of ATP into the tumor microenvironment.
• Step 2: ATP binds to P2Y2 receptors on both cancer cells and nearby tumor-associated macrophages (TAMs), activating signaling pathways.
• Step 3: P2Y2 recruits integrin β1 (a cell adhesion molecule) to form a stabilizing complex: P2Y2-integrin β1-EGFR, primarily in endosomes (cellular compartments for sorting proteins).
• Step 4: This complex prevents mutant EGFR from being trafficked to lysosomes for degradation, allowing sustained oncogenic signaling and tumor growth.
• Step 5: TAMs amplify this by secreting integrin ligands via P2Y2 activation, reinforcing protection.

When researchers knocked out P2Y2 in resistant cells, mutant EGFR levels plummeted by nearly 100%, restoring drug sensitivity. This intricate interplay demonstrates how cancer co-opts immune cells like macrophages—normally tumor-fighting allies—into protective roles.

The Pivotal Role of Tumor-Associated Macrophages in Lung Cancer Defense

Tumor-associated macrophages (TAMs), derived from circulating monocytes, infiltrate NSCLC tumors in high numbers, comprising up to 50% of the tumor mass in some cases. Traditionally polarized into pro-tumor M2-like or anti-tumor M1-like states, TAMs here act as external bodyguards.

Via P2Y2, TAMs respond to cancer-derived ATP by producing factors that stabilize EGFR on cancer cells. Depleting TAMs in mouse models mirrored P2Y2 knockout effects, shrinking tumors when combined with TKIs. This underscores TAMs' dual role in NSCLC progression: promoting immunosuppression, angiogenesis, and now, direct oncoprotein stabilization.

In Singapore's research ecosystem, such findings align with ongoing efforts at institutions like National University of Singapore (NUS) and Nanyang Technological University (NTU), where macrophage-targeted therapies are explored for higher education-driven innovation.

From Genome-Wide Screen to Mechanistic Insights: The Research Journey

The study's cornerstone was a CRISPR-Cas9 genome-wide knockout screen on PC9 cells rendered resistant to osimertinib (a third-generation EGFR TKI). Screening over 21,000 genes identified P2Y2 as the top hit.

Follow-up experiments included:

• Western blots confirming P2Y2 loss reduces EGFR protein without altering mRNA.
• Live-cell imaging showing disrupted endosomal trafficking.
• Co-immunoprecipitation validating the P2Y2-β1 integrin-EGFR complex.
• Patient-derived organoids and xenograft models demonstrating therapeutic synergy.

This rigorous approach exemplifies precision oncology research at IMCB, fostering collaborations with Singapore's universities for translational impact.

Sulforaphane: A Dietary Ally Against Drug-Resistant Lung Cancer?

Sulforaphane, a natural isothiocyanate abundant in cruciferous vegetables like broccoli, kale, and cabbage, emerged as a P2Y2 inhibitor. In preclinical tests, sulforaphane reduced mutant EGFR levels, overcame resistance, and enhanced TKI efficacy in organoids and mice.

Prior studies hinted at sulforaphane's anti-cancer properties via Nrf2 activation and EGFR modulation, but this links it directly to P2Y2. While not a standalone cure, it suggests dietary interventions as adjuvants, sparking interest in clinical trials.

Read the full study in Science Advances

Lung Cancer Burden in Singapore: A Local Perspective

Lung cancer remains Singapore's top cancer killer for men (24.6% of male cancer deaths) and third for women (15.9%), with incidence rising among never-smokers and females. In 2022, it caused significant mortality despite declining smoking rates, driven by EGFR mutations in 40-60% of adenocarcinomas.

This IMCB discovery holds particular relevance amid Singapore's National Precision Medicine program and rising cases (~1,500 annually), positioning A*STAR as a hub for academic research excellence.

Broader Implications for NSCLC Treatment and Resistance Strategies

Globally, EGFR-mutant NSCLC affects millions, with resistance curbing TKI benefits (median progression-free survival ~18 months). Targeting P2Y2 could extend this, especially via small molecules or macrophage depletion (e.g., CSF1R inhibitors).

The study opens doors to combination therapies: TKIs + P2Y2 antagonists, potentially reducing reliance on harsh chemotherapies. Stakeholder views—from oncologists praising the novelty to patients hopeful for non-toxic options—highlight its promise.

A*STAR press release

Future Outlook: Clinical Trials, Challenges, and Innovations

Next steps include P2Y2 inhibitor development and Phase I trials, possibly with sulforaphane analogs for better bioavailability. Challenges: off-target effects, TAM heterogeneity. Singapore's ecosystem, with Duke-NUS and IMCB synergies, positions it for leadership.

• Potential: Repurposed drugs blocking ATP-P2Y2.
• Risks: Resistance evolution.
• Outlook: Personalized medicine via EGFR/P2Y2 profiling.

Opportunities in Singapore's Cancer Research Landscape

This discovery underscores vibrant opportunities for researchers. Singapore universities and A*STAR offer research jobs, postdocs in oncology, and faculty positions. Explore postdoc roles or career advice to join the fight.

For aspiring academics, check Rate My Professor for insights into mentors driving such breakthroughs.

Photo by Sraboni Basu on Unsplash

Conclusion: A Shield Dismantled, Hope Restored

The lung cancer bodyguard system revelation marks a pivotal advance, blending molecular biology, immunology, and dietary science. By disarming P2Y2-mediated protection, we edge closer to conquering EGFR-driven NSCLC. Stay informed via higher education news and pursue paths in university jobs, higher ed jobs, and career advice.